Baxter continues to streamline, announcing today that it will sell its pharma and biotech contract manufacturing business. The Deerfield, Illinois-based medtech company — maker of diagnostic, critical care, kidney care, nutrition, hospital and surgical products and services — will sell its BioPharma Solutions (BPS) business to private equity firms Advent International and Warburg Pincus. Baxter…
Biopharma company Chiesi appoints former Medtronic exec as CEO
Chiesi announced today that it appointed former Baxter and Medtronic executive Giuseppe Accogli as its new group CEO. Parma, Italy–based Chiesi said Accogli’s appointment becomes effective April 3, 2023. The R&D-focused pharmaceutical company develops and commercializes products for the hospital, rare disease and adjacent specialty care settings. Accogli brings 25 years of international experience to…
Baxter may look to sell off BioPharma business
Baxter (NYSE:BAX) today unveiled a strategic roadmap for its future that includes potential plans for its BioPharma Solutions (BPS) business. The company’s plans include a simplified commercial and manufacturing footprint, according to a news release. The company also intends to improve its capital structure. That includes a review of strategic alternatives for its BioPharma Solutions…
Baxter issues Class 1 recall of Clearlink Basic Solution Sets with Duovent
The FDA has classified a recall of a Baxter Healthcare product used to deliver hazardous drugs such as chemotherapeutic agents Class 1, indicating that it could cause serious adverse health consequences or death. The recall covers all lots with product code 2R8403 distributed from October 14, 2020 to June 30, 2022. There are Baxter announced…
Baxter recall of drug compounding software is Class I
The FDA issued a notice today announcing that the recall of the Baxter Abacus software is Class I, the most serious kind. Baxter designed its Abacus order entry and calculation software to perform calculations for compounding liquid doses of medications. When connected to a compounded that mixes doses according to the calculation, the software can…
Baxter bolsters fill-finish capabilities with $100M investment in Germany
Baxter International (NYSE:BAX) plans to invest roughly $100 million to expand a sterile fill-finish manufacturing plant in Halle/Westfalen, Germany. BioPharma Solutions (BPS), a subsidiary of Deerfield, Illinois–based Baxter, will manage the new facility. BPS supports pharmaceutical companies through a range of offerings, including scientific support, sterile contract manufacturing and parenteral delivery systems. Baxter anticipates that…
Baxter to make Moderna COVID-19 vaccine in US
Baxter announced that its Baxter BioPharma Solutions business will make Moderna‘s COVID-19 vaccine at its fill/finish sterile manufacturing facilities in Bloomington, Ind. The plan — announced yesterday — is for Baxter to make 60–90 million doses of the Moderna vaccine in 2021. “We have seen a remarkable demonstration of scientific and health care expertise in…
Baxter BioPharma invests $50M in fill/finish manufacturing plant
Baxter (NYSE:BAX) is planning on spending $50 million to expand a sterile fill/finish manufacturing facility in Bloomington, Ind. Baxter’s BioPharma Solutions business will manage the site, including a new 25,000-ft2 warehouse, a new filling line for flexible plastic containers and a high-speed automated syringe fill line. Baxter hopes to wrap up manufacturing at the site in…